Abstract
We herein review experimental and theoretical approaches widely applied to delineation of the differences in substrate specificities between human and parasite phosphoribosyltransferases (PRTases), the latter of which are key targets for treatment of diseases caused by parasites. Standard Molecular Dynamics (MD) simulations have been applied to determine why the human PRTase prefers guanine over xanthine, whereas the Tritrichomonas foetus enzyme exhibits only a slight preference. We analyze this problem with the aid of standard MD simulations, as well as constant-pH MD simulations. Comparison of results of the two approaches reveals substantial differences, e.g. several Asp and Glu residues in the parasite enzyme, and one Glu residue in the human enzyme, are predicted to be permanently or frequently protonated during constant-pH simulations, whereas standard MD simulations assume that these residues are always ionized. Most interesting is the observation of a large conformational change, leading to tighter binding of the ligand, observed in constant-pH MD simulations of the parasite PRTase complexed with XMP, and lack of such a change in the human enzyme complexed with XMP.
Keywords: Ionization states of functional groups, substrate tautomerism, chemotherapy, standard and constant-pH molecular dynamics.
Current Pharmaceutical Design
Title:Resolving Differences in Substrate Specificities between Human and Parasite Phosphoribosyltransferases via Analysis of Functional Groups of Substrates and Receptors
Volume: 19 Issue: 23
Author(s): Zofia Gasik, David Shugar and Jan M. Antosiewicz
Affiliation:
Keywords: Ionization states of functional groups, substrate tautomerism, chemotherapy, standard and constant-pH molecular dynamics.
Abstract: We herein review experimental and theoretical approaches widely applied to delineation of the differences in substrate specificities between human and parasite phosphoribosyltransferases (PRTases), the latter of which are key targets for treatment of diseases caused by parasites. Standard Molecular Dynamics (MD) simulations have been applied to determine why the human PRTase prefers guanine over xanthine, whereas the Tritrichomonas foetus enzyme exhibits only a slight preference. We analyze this problem with the aid of standard MD simulations, as well as constant-pH MD simulations. Comparison of results of the two approaches reveals substantial differences, e.g. several Asp and Glu residues in the parasite enzyme, and one Glu residue in the human enzyme, are predicted to be permanently or frequently protonated during constant-pH simulations, whereas standard MD simulations assume that these residues are always ionized. Most interesting is the observation of a large conformational change, leading to tighter binding of the ligand, observed in constant-pH MD simulations of the parasite PRTase complexed with XMP, and lack of such a change in the human enzyme complexed with XMP.
Export Options
About this article
Cite this article as:
Gasik Zofia, Shugar David and Antosiewicz Jan M., Resolving Differences in Substrate Specificities between Human and Parasite Phosphoribosyltransferases via Analysis of Functional Groups of Substrates and Receptors, Current Pharmaceutical Design 2013; 19 (23) . https://dx.doi.org/10.2174/1381612811319230007
DOI https://dx.doi.org/10.2174/1381612811319230007 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Conference Report [IANR V and 9th GCNN Conference with 4th ISCITT Symposium]
CNS & Neurological Disorders - Drug Targets Implication of Rho GTPases in Neurodegenerative Diseases
Current Drug Targets Pharmacological Studies of Smooth Pursuit and Antisaccade Eye Movements in Schizophrenia: Current Status and Directions for Future Research
Current Neuropharmacology Patient Involvement and Shared Decision-Making in Mental Health Care
Current Clinical Pharmacology Promote Recurrent Aphthous Ulcer Healing with Low Dose Prednisolone Bilayer Mucoadhesive Buccal Film
Current Drug Delivery Observation of Pain in Dementia
Current Alzheimer Research Delivery of Therapeutic Proteins: Challenges and Strategies
Current Drug Targets Dopamine and the Diseased Brain
CNS & Neurological Disorders - Drug Targets Cancer Treatment-Induced Cardiotoxicity: a Cardiac Stem Cell Disease?
Cardiovascular & Hematological Agents in Medicinal Chemistry Organotypic Cultures as Tools for Testing Neuroactive Drugs – Link Between In-Vitro and In-Vivo Experiments
Current Medicinal Chemistry Steroid Hormones and Sleep Regulation
Mini-Reviews in Medicinal Chemistry Going up in Smoke? A Review of nAChRs-based Treatment Strategies for Improving Cognition in Schizophrenia
Current Pharmaceutical Design Creatine Supplementation: Can it Improve Quality of Life in the Elderly without Associated Resistance Training?
Current Aging Science Clinical Management of Secretion Retention in Critically Ill Patients who are Intubated and Mechanically Ventilated
Current Respiratory Medicine Reviews Sauropus androgynus Leaves for Health Benefits: Hype and the Science
The Natural Products Journal In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson’s Disease
Current Neuropharmacology Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews Subacute Fluoxetine Reduces Signs of Hippocampal Damage Induced by a Single Convulsant Dose of 4-Aminopyridine in Rats
CNS & Neurological Disorders - Drug Targets COVID-19, the Brain, and the Future: Is Infection by the Novel Coronavirus a Harbinger of Neurodegeneration?
CNS & Neurological Disorders - Drug Targets